Abstract:There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

Gut microbiota and therapy for obesity and type 2 diabetes

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes

Importance of gut microbiota in obesity

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Prebiotics to manage the microbial control of energy homeostasis

The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases

Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes

Intestinal microbiota and their metabolic contribution to type 2 diabetes and obesity

Exploring the Gut Microbiota: Key Insights into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes

The interaction between microbiome and host central nervous system: the gut-brain axis as a potential new therapeutic target in the treatment of obesity and cardiometabolic disease

The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes

Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?

Gut microbiota in obesity and metabolic disorders

Gut microbial metabolites in obesity, NAFLD and T2DM

The role of Gut Microbiota in the development of obesity and Diabetes

The microbiome's influence on obesity: mechanisms and therapeutic potential

Probiotic strains and mechanistic insights for the treatment of type 2 diabetes

Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus

Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus